Skip to main content
. 2023 Jan 5;15(2):352. doi: 10.3390/cancers15020352

Figure 1.

Figure 1

Post-HCT outcomes for 979 adults with AML undergoing allogeneic HCT while in first or second morphologic remission, stratified by disease status at diagnosis (de novo vs. therapy-related vs. antecedent hematologic disorder); (A) Non-relapse mortality; (B) relapse; (C) relapse-free survival; and (D) overall survival.